LON:CRTX CRISM Therapeutics Final Earnings Results & Report GBX 8 -0.25 (-3.03%) As of 04:14 AM Eastern CRISM Therapeutics reported Final earnings on June 13, 2025. The company reported EPS of -GBX 0.01. Research:ProfileEarnings History Earnings Announcement Details QuarterFinalReport DateJune 13, 2025TimeBefore Market Opens CRISM Therapeutics EPS ResultsActual EPS-GBX 0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACRISM Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile CRISM Therapeutics Final Earnings FAQ Did CRISM Therapeutics beat earnings estimates for Final? CRISM Therapeutics (LON:CRTX) reported earnings of -GBX 0.01 per share for Final. The report was announced on Friday, June 13, 2025. CRISM Therapeutics Earnings HeadlinesCRISM Therapeutics Sets AGM Date as Phase 2 Glioblastoma Trial Recruitment BeginsOctober 2, 2026 | tipranks.comCRISM Therapeutics Reveals Concentrated Shareholder Base After Register AnalysisJuly 27, 2026 | tipranks.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders. | Base Camp Trading (Ad)CRISM Therapeutics Upsizes Oversubscribed Retail Offer to Fund Cancer Drug Delivery TrialsMay 28, 2026 | tipranks.comCRISM Therapeutics Raises Funds for Glioblastoma TrialDecember 15, 2025 | tipranks.comCRISM Therapeutics Launches £100,000 Retail Offer to Fund Clinical TrialDecember 10, 2025 | tipranks.comSee More CRISM Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CRISM Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISM Therapeutics and other key companies, straight to your email. Email Address About CRISM TherapeuticsCRISM Therapeutics (LON:CRTX) is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026. For more information please visit: https://www.crismtherapeutics.comView CRISM Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
